Diagnosing and Staging DLBCL Using Label-Free Surface-Enhanced Raman Spectroscopy

By Robert Dillard - Last Updated: November 16, 2021

A study shows that label-free surface-enhanced Raman spectroscopy (SERS) in combination with descriptive analysis may effectively stage diffuse large B-cell lymphoma (DLBCL). The results were published in Molecular and Biomolecular Spectroscopy.

Non-invasive diagnosis and staging of DLBCL were achieved using label-free SERS, with spectras measured for serum samples of DLBCL patients at different progressive stages and healthy controls, using colloidal silver nanoparticles (AgNPs) as the substrate.

Researchers observed differences in the spectral intensities of Raman peaks between the DLBCL and control groups. There was also a close correlation between the spectral intensities of Raman peaks with the progressive stages of DLBCL, which the researchers noted demonstrates the possibility of diagnosis and staging of the disease using the serum SERS spectra. Through multivariate analysis methodology, including principal component analysis, linear discriminant analysis, support vector machine classifier, and k-nearest neighbors (kNN) classifier, the investigators developed the diagnosis and staging models for DLBCL. Leave-one-out cross-validation was used to assess the model’s performance.

The kNN model achieved robust results with respect to both diagnosing and staging of DLBCL. For the diagnosis analysis, the accuracy, sensitivity, and specificity were 87.3%, 0.921, and 0.809, respectively; for the staging analysis between the early (Stage I & II) and the late (Stage III & IV) stages, the accuracy was 90.6%, and the sensitivity values for the early and the late stages were 0.947 and 0.800, respectively.

“The label-free serum SERS in combination with multivariate analysis could serve as a potential technique for non-invasive diagnosis and staging of DLBCL,” the researchers concluded.

Post Tags:DLBCL